ACTIV- Exercise Intervention in Healthy Young Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to compare muscle energy capacity in men with obesity or diabetes as compared to athletes. This study will also enable researchers to determine whether MRS can replace muscle biopsy for this type of assessment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men

NCT01787617

Insulin Resistance Type 2 Diabetes

COMPLETED NA

Effect of Exercise on Metabolic Health

NCT02001142

Obesity

COMPLETED NA

Metabolic Adaptations to Chronic and Acute Exercise in Overweight Adults (ATX-Study)

NCT02701751

Healthy

COMPLETED NA

Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors

NCT05123963

Prediabetic State

RECRUITING NA

Exercise Effects on Adipose Tissue Structure and Function

NCT04812314

Obesity Metabolic Syndrome Metabolic Disease +3 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Skeletal muscle mitochondrial defects are a sine qua non of insulin resistance in patients with type 2 diabetes mellitus (T2DM), obese and subjects with family history of T2DM (FH+). Exercise increases mitochondrial capacity whereas lipid infusion or high fat diet decreases genes involved in mitochondrial biogenesis. In this study 2 cohorts will be involved: Cohort I (athletes, T2DM and obese) and Cohort II (healthy with "FH+" or without "FH-" family history of T2DM). This randomized, parallel arm clinical trial will consist of 4 periods: screening, stabilization (3 days), baseline (for Cohort I and II) and exercise period (14 days, only for Cohort II). The overall objective of the study is to validate a paradigm for the evaluation of compounds and drugs that activate mitochondrial biogenesis in skeletal muscle. In Specific Aim 1 we will compare and contrast biopsy and MRS power to detect differences in mitochondrial capacity in 78 subjects: athletes (N=10), FH- (N=24), FH+ (N=24), obese (N=10) and T2DM (N=10). In Specific Aim 2 we will compare mitochondrial changes in response to exercise in subjects FH - vs. FH + subjects. In Specific Aim 3 we will determine if HFD impairs mitochondrial changes in response to exercise in FH+ subjects. In Specific Aim 4 we will determine the role of mitochondrial capacity in metabolic flexibility and insulin sensitivity in T2DM, obese, FH+, FH- and athlete subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

Exercise

Intervention Type BEHAVIORAL

* Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period
* Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer.

2

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise

* Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period
* Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aerobic and interval exercise training

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

T2DM group:

* Men aged 25-35
* BMI \> 30 kg/m2
* Sedentary lifestyle determined by activity index questionnaire (not involved in regular exercise program) and accelerometer data.
* Are willing to eat only foods provided by Pennington for the study period
* Diagnosed with T2DM defined by one or more of the following:

* fasting plasma glucose \> 126 mg/dL at entry
* a two-hour OGTT glucose \> 200mg/dL
* current medication for T2DM

Obese group:

* Men aged 25-35
* BMI \> 30 kg/m2
* Sedentary lifestyle activity index questionnaire (not involved in regular exercise program) and accelerometer data.
* Are willing to eat only foods provided by Pennington for the study period

FH+ group:

* Men aged 25-35
* One parent diagnosed with T2DM
* fasting insulin \> 10mIU/ml (\> 50th %tile)
* BMI between 22 and 30 kg/m2
* Sedentary lifestyle activity index questionnaire (not involved in regular exercise program) and accelerometer data.
* Are willing to exercise every day for the study period
* Are willing to eat only foods provided by Pennington for the study period

FH- group:

* Men aged 25-35
* Parents and grandparents were not diagnosed with T2DM
* Fasting insulin \< 10mIU/ml (\< 50th %tile)
* BMI between 22 and 30 kg/m2
* Sedentary lifestyle activity index questionnaire (not involved in regular exercise program) and accelerometer data.
* Are willing to exercise for the study period
* Are willing to eat only foods provided by Pennington for the study period

Athlete group:

* Men aged 25-35
* Maximal oxygen uptake \> 60 ml/kg.min
* Are engaged in minimum of 1.5 h of aerobic exercise 3 times/ week
* Are willing to eat only foods provided by Pennington for the study period

Exclusion Criteria

* Abnormal resting or exercise ECG
* Significant renal, cardiac, liver, lung, or neurological disease (controlled hypertension is acceptable if baseline bp \< 140/90 on medications)
* Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc
* Alcohol or other drug abuse
* Smoking
* Gait problems
* Unwilling or unable to abstain from caffeine (48h) prior to metabolic rate measurements
* Unwilling or unable to eat all study foods
* Increased liver function tests at baseline (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal)
* Metal objects that would interfere with the measurement of body composition /MRS such as implanted rods, surgical clips, etc
* NYHA class III/IV CHF is an exclusionary cardiac condition
* history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
* varicose veins
* major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
* cancer (active malignancy with or without concurrent chemotherapy)
* rheumatoid disease
* bypass graft in limb
* known genetic factor (Factor V Leiden, etc) or hypercoagulable state
* diagnosed peripheral arterial or vascular disease, or intermittent claudication
* family history of primary DVT or PE (pulmonary embolism)
* peripheral neuropathy

Minimum Eligible Age

25 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes